The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes.

IF 5.2 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Atherosclerosis Reports Pub Date : 2025-07-30 DOI:10.1007/s11883-025-01319-6

Kyle Sheth, Stephanie Kim, Laura Porterfield, Salim S Virani, Shikha Wadhwani, Elizabeth M Vaughan

{"title":"The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes.","authors":"Kyle Sheth, Stephanie Kim, Laura Porterfield, Salim S Virani, Shikha Wadhwani, Elizabeth M Vaughan","doi":"10.1007/s11883-025-01319-6","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review summarizes recent advances in the clinical applications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond their established role in glycemic control for type 2 diabetes (T2DM).Recent findings: Originally developed for glycemic control in T2DM, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now being utilized for a range of additional diseases and conditions. Strong evidence supports their efficacy in inducing clinically meaningful weight loss in individuals with overweight or obesity. Further studies have demonstrated cardiovascular benefits, kidney-protective effects, and therapeutic potential in obesity-related conditions such as obstructive sleep apnea and metabolic-associated steatotic liver disease. Emerging data also suggest possible roles in treating substance use disorders, including alcohol and nicotine dependence, though findings remain preliminary and variable. Despite these promising developments, GLP-1RAs are associated with side effects and high costs, contributing to variability in patient access. The therapeutic scope of GLP-1 receptor agonists extends beyond diabetes to multiple other conditions. Broader adoption requires careful evaluation of safety, cost, and evidence for less-established indications.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"76"},"PeriodicalIF":5.2000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Atherosclerosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11883-025-01319-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review summarizes recent advances in the clinical applications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond their established role in glycemic control for type 2 diabetes (T2DM).

Recent findings: Originally developed for glycemic control in T2DM, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now being utilized for a range of additional diseases and conditions. Strong evidence supports their efficacy in inducing clinically meaningful weight loss in individuals with overweight or obesity. Further studies have demonstrated cardiovascular benefits, kidney-protective effects, and therapeutic potential in obesity-related conditions such as obstructive sleep apnea and metabolic-associated steatotic liver disease. Emerging data also suggest possible roles in treating substance use disorders, including alcohol and nicotine dependence, though findings remain preliminary and variable. Despite these promising developments, GLP-1RAs are associated with side effects and high costs, contributing to variability in patient access. The therapeutic scope of GLP-1 receptor agonists extends beyond diabetes to multiple other conditions. Broader adoption requires careful evaluation of safety, cost, and evidence for less-established indications.

查看原文本刊更多论文

GLP-1受体激动剂的应用范围扩大：除糖尿病外的六种用途

综述目的：本文综述了胰高血糖素样肽-1受体激动剂（GLP-1RAs）在2型糖尿病（T2DM）血糖控制中的作用之外的临床应用进展。最近发现：胰高血糖素样肽-1受体激动剂（GLP-1RAs）最初是为控制T2DM的血糖而开发的，现在被用于一系列其他疾病和病症。强有力的证据支持它们在超重或肥胖个体中诱导临床有意义的体重减轻的功效。进一步的研究表明，它对心血管有益，对肾脏有保护作用，对肥胖相关疾病（如阻塞性睡眠呼吸暂停和代谢相关的脂肪变性肝病）有治疗潜力。新出现的数据还表明，它可能在治疗物质使用障碍（包括酒精和尼古丁依赖）方面发挥作用，尽管研究结果仍处于初步阶段，而且存在变数。尽管有这些有希望的发展，GLP-1RAs与副作用和高成本相关，导致患者获得的可变性。GLP-1受体激动剂的治疗范围不仅限于糖尿病，还包括多种其他疾病。更广泛的采用需要仔细评估安全性、成本和针对不太确定适应症的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Atherosclerosis Reports 医学-

CiteScore

9.00

自引率

3.40%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.